QTTB revenueFY2025$53.74M
- 5Y CAGR
- +81.9%
QTTB revenue was $53.74M for fiscal 2025 (ended Dec 31, 2025), compared with $0 in fiscal 2024. Compound annual growth was +81.9% over 5 years. Fiscal 2025 is the highest of the 8 fiscal years on file.
Q32 Bio Inc. (QTTB) financials
For fiscal 2025 (ended Dec 31, 2025), Q32 Bio Inc. reported $53.74M of revenue and $29.82M of net income.
- Revenue, FY2025
- $53.74M
- Net income, FY2025
- $29.82M
- Net margin
- 55.5%
- Free cash flow, FY2025
- -$33.54M
- EPS, diluted, FY2025
- $2.42
- Cash
- $289.59M
- P/E
- 9.28
- P/S
- 5.15
- Market cap
- $276.8M
FY2018FY2025
FY2017FY2025
FY2017FY2025
QTTB revenue and earnings growth
QTTB net incomeQ3 2026-$8.92M
QTTB net income was -$8.92M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$7.39M a year earlier. For the full fiscal 2025 it was $29.82M, compared with -$47.73M in fiscal 2024. Fiscal 2025 is the highest of the 9 fiscal years on file.
QTTB EPSQ3 2026-$0.26
QTTB diluted EPS was -$0.26 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was $2.42, compared with -$6.58 in fiscal 2024.
QTTB free cash flowQ4 2025-$6.18M
QTTB free cash flow was -$6.18M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$11.43M a year earlier. For the full fiscal 2025 it was -$33.54M, compared with -$67.79M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $53.74M | $0 | -$6.65M | $3.21M | $33.97M | $2.70M | $1.67M | $5.32M | - |
| Research and development | $19.16M | $48.14M | $31.73M | $98.35M | $93.08M | $100.39M | $89.40M | $47.95M | $21.38M |
| Selling, general and admin | $17.68M | $17.96M | $9.88M | $38.14M | $36.84M | $32.57M | $22.21M | $17.30M | $8.28M |
| Operating income | $16.90M | -$66.10M | -$48.26M | -$133.28M | -$95.95M | -$130.26M | -$109.94M | -$59.93M | -$29.66M |
| Pre-tax income | $29.82M | -$46.09M | -$53.42M | $1.20M | -$95.76M | - | - | - | - |
| Income tax | $0 | $21.0K | $318.0K | $715.0K | $0 | $0 | $0 | $0 | $0 |
| Net income | $29.82M | -$47.73M | -$53.74M | -$5.00M | -$95.76M | -$128.69M | -$103.92M | -$55.58M | -$29.99M |
| EPS, basic | $2.42 | -$5.12 | -$153.96 | -$0.09 | -$1.73 | -$2.80 | -$2.47 | -$1.95 | -$12.10 |
| EPS, diluted | $2.42 | -$6.58 | -$153.96 | -$0.09 | -$1.73 | -$2.80 | -$2.47 | -$1.95 | -$12.10 |
| Diluted shares | 12.3M | 9.7M | 349,060 | 57.4M | 55.3M | 45.9M | 42.1M | 28.6M | 2.5M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $48.30M | $78.61M | $31.26M | $49.54M | $108.38M | $217.43M | $53.77M | $38.22M | $51.58M |
| Short-term investments | - | $0 | $0 | $141.04M | - | - | - | - | - |
| Current assets | $55.05M | $81.88M | $28.72M | $181.01M | $191.91M | $219.56M | $266.58M | $221.69M | $131.60M |
| Total assets | $61.78M | $92.33M | $47.06M | $228.47M | $211.72M | $263.74M | $310.57M | $259.09M | $137.53M |
| Current liabilities | $11.35M | $16.46M | $14.11M | $22.58M | $17.23M | $22.66M | $12.37M | $22.52M | $8.86M |
| Total liabilities | $19.76M | $86.66M | $118.53M | $50.49M | $42.07M | $67.74M | $52.06M | $62.74M | $39.22M |
| Shareholders' equity | $42.01M | $5.67M | -$182.92M | -$130.71M | $169.65M | $196.00M | $258.51M | $196.35M | -$39.45M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$33.54M | -$67.72M | -$18.68M | -$113.66M | -$109.75M | -$94.33M | -$91.36M | -$42.56M | $6.48M |
| Capital expenditures | $0 | $75.0K | $5.0K | $1.28M | $2.40M | $3.73M | $21.83M | $24.94M | $1.96M |
| Free cash flow | -$33.54M | -$67.79M | -$18.68M | -$114.95M | -$112.15M | -$98.06M | -$113.19M | -$67.50M | $4.52M |
| Investing cash flow | $7.00M | $19.93M | -$5.0K | $36.72M | -$50.79M | $204.90M | -$51.80M | -$121.79M | -$81.53M |
| Financing cash flow | -$3.13M | $95.14M | $406.0K | $596.0K | $52.17M | $53.09M | $158.21M | $150.99M | $115.23M |
| Stock-based compensation | $5.25M | $4.39M | $1.43M | $13.05M | $17.25M | $13.25M | $7.63M | $2.62M | $277.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | -307.3% | -90.6% | 1157.3% | 62.2% | -68.7% | - | - |
| Operating margin | 31.5% | - | - | -4154.6% | -282.4% | -4821.0% | -6599.2% | -1126.0% | - |
| Net margin | 55.5% | - | - | -156.0% | -281.9% | -4762.9% | -6237.5% | -1044.3% | - |
| Free cash flow margin | -62.4% | - | - | -3583.1% | -330.1% | -3629.3% | -6794.2% | -1268.3% | - |
| Return on equity | 71.0% | -841.1% | - | - | -56.4% | -65.7% | -40.2% | -28.3% | - |
| Return on assets | 48.3% | -51.7% | -114.2% | -2.2% | -45.2% | -48.8% | -33.5% | -21.5% | -21.8% |
| Current ratio | 4.85 | 4.97 | 2.04 | 8.02 | 11.14 | 9.69 | 21.54 | 9.84 | 14.85 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $0 | $0 | $0 | $0 | -$14.66M |
| Research and development | $5.15M | $4.26M | $3.22M | $3.31M | $3.56M | $5.16M | $7.12M | $10.54M | $14.35M | $13.41M | $9.84M | $8.34M |
| Selling, general and admin | $5.51M | $4.86M | $4.50M | $4.54M | $4.02M | $4.01M | $5.10M | $3.98M | $4.47M | $4.51M | $5.00M | $2.81M |
| Operating income | -$10.66M | -$9.12M | -$7.72M | $45.88M | -$7.58M | -$9.17M | -$12.23M | -$14.53M | -$18.81M | -$17.92M | -$14.84M | -$25.81M |
| Pre-tax income | - | - | - | $57.73M | -$7.39M | -$9.49M | -$11.03M | -$14.17M | -$17.59M | -$15.53M | $1.21M | -$26.81M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $21.0K | $0 | $0 | $0 | $383.0K |
| Net income | -$8.92M | -$8.95M | -$7.61M | $57.73M | -$7.39M | -$9.49M | -$11.03M | -$14.19M | -$17.59M | -$16.98M | $1.03M | -$27.07M |
| EPS, basic | -$0.26 | -$0.44 | -$0.54 | $4.70 | -$0.60 | -$0.78 | -$0.90 | - | -$1.46 | -$1.42 | $1.03 | -$76.91 |
| EPS, diluted | -$0.26 | -$0.44 | -$0.54 | $4.70 | -$0.60 | -$0.78 | -$0.90 | - | -$1.46 | -$1.42 | -$6.33 | -$76.91 |
| Diluted shares | 34.0M | 20.3M | 14.1M | - | 12.2M | 12.2M | 12.2M | - | 12.1M | 12.0M | 2.3M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $289.59M | $106.27M | $50.75M | $48.30M | $49.04M | $54.83M | $65.48M | $78.61M | $89.08M | $97.66M | $115.51M | $31.26M |
| Short-term investments | - | - | - | - | - | - | - | $0 | $0 | - | - | $0 |
| Current assets | $291.13M | $109.65M | $57.20M | $55.05M | $50.81M | $58.32M | $68.63M | $81.88M | $93.90M | $111.62M | $138.04M | $28.72M |
| Total assets | $297.20M | $115.87M | $63.67M | $61.78M | $57.78M | $66.12M | $79.07M | $92.33M | $104.54M | $124.21M | $152.33M | $47.06M |
| Current liabilities | $5.17M | $5.40M | $10.67M | $11.35M | $11.11M | $11.53M | $14.58M | $16.46M | $14.38M | $17.19M | $32.95M | $14.11M |
| Total liabilities | $9.53M | $9.96M | $17.36M | $19.76M | $76.23M | $78.35M | $83.08M | $86.66M | $86.25M | $90.70M | $103.56M | $118.53M |
| Shareholders' equity | $287.67M | $105.91M | $46.31M | $42.01M | -$18.45M | -$12.23M | -$4.01M | $5.67M | $18.30M | $33.51M | $48.77M | -$182.92M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.42M | -$3.08M | -$6.34M | -$6.18M | -$4.23M | -$10.65M | -$12.48M | -$11.43M | -$19.52M | -$22.21M | -$14.55M | -$10.71M |
| Capital expenditures | - | - | - | $0 | $0 | - | - | $2.0K | $58.0K | $15.0K | $0 | $0 |
| Free cash flow | - | - | - | -$6.18M | -$4.23M | - | - | -$11.43M | -$19.58M | -$22.23M | -$14.55M | -$10.71M |
| Investing cash flow | -$52.0K | $0 | $0 | $7.00M | $0 | $0 | $0 | -$2.0K | $9.94M | $9.89M | $97.0K | $0 |
| Financing cash flow | $187.79M | $58.59M | $8.80M | -$1.56M | -$1.56M | - | - | $317.0K | $997.0K | -$5.52M | $99.35M | $76.0K |
| Stock-based compensation | $2.90M | $1.69M | $1.55M | $1.47M | $1.18M | $1.27M | $1.34M | $1.25M | $1.38M | $1.34M | $417.0K | $521.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | -100.0% | -100.0% | -100.0% | -1928.2% |
| Current ratio | 56.34 | 20.30 | 5.36 | 4.85 | 4.57 | 5.06 | 4.71 | 4.97 | 6.53 | 6.49 | 4.19 | 2.04 |
Source: XBRL data Q32 Bio Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
QTTB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| QTTB | $53.74M | - | $29.82M | 55.5% | $276.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
QTTB FAQ
7 questionsWhat is QTTB revenue?
Q32 Bio Inc. (QTTB) reported $53.74M of revenue for fiscal 2025 (ended Dec 31, 2025).Is QTTB profitable?
Yes. Q32 Bio Inc. earned $29.82M in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 55.5%.How much cash and debt does QTTB have?
Q32 Bio Inc. reported $289.59M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is QTTB free cash flow?
Q32 Bio Inc. generated -$33.54M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$33.54M less capital expenditures.What is QTTB earnings per share?
Diluted earnings per share were $2.42 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did QTTB last report financial results?
The latest statements here come from Q32 Bio Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.Where does this QTTB financial data come from?
Quantisnow builds these statements from the structured XBRL data Q32 Bio Inc. files with the SEC. It is provided for information only and is not investment advice.